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 Research was carried out to obtain a selective ligand which strongly bind to 
estrogen receptors through determination of binding affinity of estradiol-17β-
hemisuccinate. Selectivity of these compounds for estrogen receptor was studied 
using Scintillation Proximity Assay (SPA) method.  Primary reagents required in 
the SPA method including radioligand and receptor, the former was obtained by 
labeling of estradiol-17β-hemisuccinate with 125I, while MCF7 was used as the 
receptor. The labeling process was performed by indirect method via two-stage 
reaction. In this procedure, first step was activation of estradiol-17β-hemisuccinate 
using isobutylchloroformate and tributylamine as a catalist, while labeling of 
histamine with 125I was carried out using chloramin-T method to produce 
125I-histamine. The second stage was conjugation of activated estradiol-17β-
hemisuccinate with 125I-histamine. The product of estradiol-17β-hemisuccinate
labeled 125I was extracted using toluene. Furtherly, the organic layer was purified by 
TLC system. Characterization of estradiol-17β-hemisuccinate labeled 125I from this 
solvent extraction was carried out by determining its radiochemical purity and the 
result was obtained using paper electrophoresis and TLC were 79.8% and 84.4% 
respectively. Radiochemical purity could be increased when purification step was 
repeated using TLC system, the result showed up to 97.8%. Determination of
binding affinity by the SPA method was carried out using MCF7 cell lines which
express estrogen receptors showed the value of Kd at 7.192 x 10-3 nM and
maximum binding at 336.1 nM. This low value of Kd indicated that binding affinity 
of estradiol-17β-hemisuccinate was high or strongly binds to estrogen receptor. 
 
© 2012 Atom Indonesia. All rights reserved
 
INTRODUCTION∗ 
 
Breast cancer is a malignant condition of  the 
cells contained in the breast. Breast cancer is one of 
the leading causes of cancer death among women 
and more than one million cases a year are found 
around the world [1]. Molecular mechanisms of 
breast cancer  begin with a mutation in the normal 
gene. Mutation occur are usually point mutations, 
among others, could caused to rearrangement or 
deletion [1]. Two-thirds of breast cancers express 
estrogen receptor (ER). The ER status is important 
as a prognostic indicator in breast cancer. Women 
                                                
∗ Corresponding author. 
   E-mail address: veronika@batan.go.id 
with estrogen receptor positive breast tumors have a 
better prognosis than women with estrogen receptor 
negative tumors in the treatment with the 
antiestrogen [2]. 
Estrogen receptor is one of the intracellular 
receptor (nuclear receptor) that mediates the action 
of 17β-estradiol (estrogen) hormone in the body. 
The presence of estrogen is able to initiate growth, 
proliferation and metastasis of various types of 
cancers (breast, ovarian, colorectal, prostate, and 
endometrial) [3].  
If an estrogen receptor (ER) binds to the 
ligand, there will be a change in receptor 
conformation that allows binding with coactivator. 
Estrogen receptor complex then binds with estrogen 
receptor element (ERE). After binding with ERE, 
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the complex binds to a protein coactivator and  
activates transcription factors. Activation of gene 
transcription was going to produce mRNA that 
directs the synthesis of specific proteins, which then 
affects cell function, depending on their target           
cells [4].  
Ligand that would bind to estrogen receptors 
was then compete with estrogen for binding to its 
receptor and was called Selective Estrogen Receptor 
Modulators (SERMs). This selectivity may be 
achieved due to the estrogen receptor in different 
tissues vary in their chemical structure that allows a 
group of SERMs drugs to selectively interact on 
estrogen receptors in certain tissues [4]. 
To obtain a selective ligand which strongly 
bind to estrogen receptor, study is needed to 
determine the selectivity of compound to be used as 
a ligand. In this study, analog of the ligand that will 
bind to estrogen receptors of the steroid compound 
will be used, which is estradiol-17β-hemisuccinate.  
The presence of hydroxyl groups on the           
C3 aromatic ring of estradiol-17β-hemisuccinate 
indicates an ability to bind to estrogen receptors. 
This is reasonable because one of pharmacophore 
was required to bind to the estrogen receptor is the 
presence of an aromatic ring substituted with a 
hydroxyl group [5]. The main frame of estradiol-
17β-hemisuccinate contributed  an estimated affinity 
for estrogen receptor α through hydrophobic 
interactions with binding of the ligand and estrogen 
receptor α [6]. 
The binding affinity of estradiol-17β-
hemisuccinate to the estrogen receptor in MCF7 cell 
lines was studied using scintillation proximity assay 
(SPA) method. The SPA is a technique which 
determine binding of antibodies or receptor 
molecules to a bead which emit light from the 
energy of labeled radioactive ligand. This                                                                                                           
occurrence triggers the release of light from the 
beads and therefore can be detected by detector [7].  
The SPA method does not require any separation or 
washing step because of its homogeneous form [8], 
thus the method is easy to be applied for drug 
screening [9]. The factors affecting the 
determination by the SPA technique are the use of 
solvent (assay buffer), the type of ligand or 
compound to be determined and the type of                
bead [10]. 
In this study determination of binding affinity 
of estradiol-17β-hemisuccinate to the estrogen 
receptor was performed by in vitro test with SPA 
method using estradiol-17β-hemisuccinate labeled 
125I. The aim of this  research is to find an optimum 
condition for preparation and purification of                
125I labeled estradiol-17β-hemisuccinate using an 
indirect method, especially to obtain the value of 
dissociation constant (Kd) and maximum binding 
(Bmax) of binding affinity of estradiol-17β-
hemisuccinate labeled 125I. The previous study 
related to this research (reference no 15) using 
radioligand binding assay method. In this study 
using SPA method, is expected to obtain a lower 
value of Kd. 
 
 
EXPERIMENTAL METHOD 
 
Indirect Labeling of Estradiol-17β-
hemisuccinate  
 
The labeling process of estradiol-17β-
hemisuccinate was performed in similar manner to 
procedure reported in Refs [11-14]. This process 
involved three stages of reactions. It was began by               
activating the estradiol-17β-hemisuccinate with 
isobutilchloroformate using tributylamine as catalyst 
to form an active compound of  estradiol-17β-
hemisuccinate-isobutylchloroformate (Fig. 1). The  
second  stage  was preparation of histamine labeled 
with 125I using chloramin-T method (Fig. 2).               
The final stage was the conjugation of  histamine  
labeled 125I to the activated estradiol-17β-
hemisuccinate-isobutylchloroformate (Fig. 3).               
The obtained 125I-estradiol-17β-hemisuccinate-
iodohistamine was then purified and tested using 
labelling efficiency and radiochemical purity 
parameters. 
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Fig. 1. Activation  of  estradiol-17β-hemisuccinate   with 
isobutilchloroformate using tributylamine as catalyst. 
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Fig. 2. Labeling histamine with 125I using chloramin-T method. 
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Fig. 3. Conjugation of 125I-histamine to the activated estradiol-
17β-hemisuccinate 
 
 
Scintillation Proximity Assay (SPA) 
 
Assay protocol with varying the amount and 
type of SPA bead 
 
In a Laminar Air Flow, a 100 µL of sterile 
phosphate buffer saline containing MCF7 cells was 
added to a plate of 96 well.  For  well of non spesific 
binding, a 25 µL of unlabeled estradiol-17β-
hemisuccinate was placed in the well, while for total 
binding the well containing a 25 µL phosphate 
buffer saline. Then a 100 µL of 125I-estradiol-17β-
hemisuccinate-iodohistamine in assay buffer and              
50 µL of SPA beads suspension were added  to each 
well. The plate was sealed and  incubated for 1 h at 
25ºC, with shaking. Final assay consentrations              
were : MCF7 cell lines of 500,000/well, 0.08 nM 
unlabeled estradiol-17β-hemisuccinate, 400 nM  
125I-estradiol-17β-hemisuccinate-iodohistamine, SPA 
beads ( 12.5 to 250 µg/µL).Varying types of beads 
were used including YSi-WGA SPA, YSi-antirabbit 
SPA dan PVT-antirabbit SPA beads. The plate was 
counted using Liquid Scintillation Counter (LSC) at 
1 min per well. Results from this experiment can 
identify the proper  type of SPA bead to be used in 
future experiments. 
 
 
Assay protocol for binding study of 125I-
estradiol-17β-hemisuccinate-iodohistamine 
[15] 
 
To each well, a 100 µL of sterile phosphate 
buffer saline containing MCF7 cells was added.            
A 25 µL of unlabeled estradiol-17β-hemisuccinate 
was placed in the well for non spesific binding. For 
total binding the well, a 25 µL phosphate buffer 
saline was added. Varying consentration of              
125I-estradiol-17β-hemisuccinate-iodohistamine as a 
tracer was diluted in  assay  buffer, then a 100 µL of  
tracer and 50 µL of SPA beads suspension were 
added to each well. The plate was sealed and 
incubated for 1 h at 25ºC, with shaking. Final assay 
consentrations : MCF7 cell lines of 500,000/well, 
0.08 nM unlabeled estradiol-17β-hemisuccinate, 
concentration of 125I-estradiol-17β-hemisuccinate-
iodohistamine  (10 nM to 400 nM), SPA beads (25 
µg/µL). The plate was counted using LSC at 1 min 
per well. Results from this experiment were used to 
calculate the value of Kd and maximum binding 
(Bmax). 
 
 
RESULTS AND DISCUSSION 
 
The labeling of estradiol-17β-hemisuccinate 
with 125I was carried out using indirect method             
[11-14]. Evaluations of labeling and radiochemical 
purity were monitored using paper electrophoresis 
and TLC. Prior to labeling process, a 
radiochromatogram of  Na-125I was prepared and 
showed in Fig. 4 for paper electrophoresis and TLC. 
Whatman paper  No. 1 was used as stationary phase 
and 0,025 M phosphate buffer pH 7,4 was used as 
mobile phase in the electrophoresis method.   While 
for TLC, silica 60F254 was used as the stationary 
phase and the mixture of chloroform : ethanol (9 : 1)   
as mobile phase. The radiochromatogram was              
used as a refference in identifying the result of 
labeling process (125I-estradiol-17β-hemisuccinate-
iodohistamine). The radiochromatogram of Na-125I 
(Fig. 4) showed the radiochemical purity at more   
than 97%, which was good enough for this research 
[13].  
 
 
      (a) 
 
             (b) 
 
 
Fig. 4. Radiochromatogram of Na-125I using paper 
electrophoresis (a) and using TLC (b). 
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The labeling process was performed by 
indirect method via two-stage reaction. First 
activation of estradiol-17β-hemisuccinate using 
isobutylchloroformate and tributylamine as a 
catalist, and labeling of histamine was carried out by 
125I using chloramin-T method. The second stage 
was conjugation of activated estradiol-17β-
hemisuccinate with 125I-histamine.  The estradiol-
17β-hemisuccinate labeled 125I was extracted using 
toluene and organic phase was purified by TLC 
system.  The   radiochemical purity of 125I-estradiol-
17β-hemisuccinate-iodohistamine was obtained at 
79.8% using paper electrophoresis while using TLC 
was 84.4% as shown in Fig. 5.  
 
 
 
 
 
Fig. 5. Radiochromatogram of 125I-estradiol-17β-hemisuccinate-
iodohistamine using paper electrophoresis (a). and using              
TLC (b). 
 
It can be seen from Fig. 5, that radiochemical 
purity of the purified 125I-estradiol-17β-
hemisuccinate-iodohistamine was still low.  
Therefore further purification was a necessary. 
Further purification was carried out by a semi-
preparative TLC glass plate of silica gel 60 F254 as 
the stationary phase and a mixture of benzene : 
ethanol :  acetic acid (75 : 24 : 1) as the mobile 
phase. Radiochromatogam of 125I-estradiol-17β-
hemisuccinate-iodohistamine purified with TLC 
system can be seen in Fig. 6.  
 
Fig. 6. Radiochromatogram of 125I-estradiol-17β-hemisuccinate-
iodohistamine using TLC glass plate. 
 
Figure 6 showed an increasing purity               
of 125I-estradiol-17β-hemisuccinate-iodohistamine. 
Increased purification yield of 125I-estradiol-17β-
hemisuccinate-iodohistamine reached 89.9%. 
Radiochemical  purity of purified 125I-estradiol-17β-
hemisuccinate-iodohistamine was then monitored by 
TLC, using silica 60 F254 as stationary phase and a 
mixture of chloroform : ethanol (9 : 1) as a mobile 
phase. Radiochromatogram for radiochemical    
purity of purified 125I-estradiol-17β-hemisuccinate-
iodohistamine was obtained at 97.8% as showed     
in Fig. 7. 
 
 
Fig. 7. Radiochromatogram of 125I-estradiol-17β-hemisuccinate-
iodohistamine using TLC. 
 
Purified 125I-estradiol-17β-hemisuccinate-
iodohistamine with high radiochemical purity was 
then used to observe its binding to estrogen 
receptors. The estrogen receptors used in this study 
was breast cancer cells (MCF7 cell lines) that 
express estrogen receptor α. The binding study 
performed after optimization on the amount and 
type of SPA beads. Various types of beads were 
used including YSI-WGA SPA, YSI-antirabbit SPA 
and PVT-antirabbit SPA. At varying amount of  
SPA beads (12.5 µg/mL to 250 µg/mL). Figure 8a. 
showed optimum beads was YSI-WGA SPA beads. 
The results showed that the YSI-WGA SPA beads 
with concentration of 25 ug/mL gave total binding 
(TB) higher than the value of non specific binding 
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(NSB). For other types of beads (YSI-antirabbit 
SPA and PVT-antirabbit SPA) gave low values of  
NSB and TB. 
After obtaining the type and amount of the 
optimum of  beads, assay protocol was performed to 
obtained value of the dissociation constant (Kd) and 
maximum binding values (Bmax). The data from 
assay protocol was radioactivity of NSB and TB. 
The data were then calculated to obtain the 
concentration of NSB and TB, then rosenthal plot 
curve was made to get linear regression equation. 
As shown in Fig. 8b, linear regression equation   
following formula y = -ax + b, y = -139.05x + 
336.1. The regression equation gave the value of  
Kd = - (1/slope) = - (1/-139,05) = 7.192 x 10-3 nM 
and maximum binding = Bmax = intercept =             
336.1 nM. The values of  Kd was requirements for 
Kd values of estradiol are based on literature at              
< 0.003 – 0.87 nM [16]. Binding affinity of 
estradiol-17β-hemisuccinate represented by the 
value of Kd at 7.192 x 10-3 nM. This low value of 
Kd indicated that binding affinity of estradiol-17β-
hemisuccinate was high or strongly bind to estrogen 
receptor. When compared with literature written by 
Neto et al, values of Kd was obtained at 6.14 nM. 
The difference in affinity is probably related to the 
ligand lipophilicity [17]. 
 
 
 
 
 
 
Fig. 8. Optimization of the type and amount of SPA bead (a),          
and Rosenthal Plot curve (b) 
CONCLUSION 
 
Preparations of 125I-estradiol-17β-
hemisuccinate-iodohistamine with indirect labelling 
method has been carried out. Two stages of 
purification, solvent extraction and TLC system, 
were managed to obtain  radiochemical purity of 
125I-estradiol-17β-hemisuccinate-iodohistamine at 
more than 90%. Purification stage yielded at 89,9% 
and the radiochemical purity at 97,8% was obtained. 
Determination of binding affinity by the SPA 
method using MCF7 cell lines which express 
estrogen receptors, represented by the value of Kd at 
7.192 x 10-3 nM and maximum binding at 336.1 nM. 
This low value of Kd indicated that binding affinity 
of estradiol-17β-hemisuccinate was high or strongly 
bind to estrogen receptor. 
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